4D Molecular Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David H. Kirn
- Full Time Employees
- 196
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5858 Horton Street EmeryVille CA United States of America 94608
- IPO Date
- Dec 11, 2020
- CIK
- 0001650648
- Website
- 4dmoleculartherapeutics.com
- Similar Companies
- Business
- 4D Molecular Therapeutics, Inc., founded in 2013 and headquartered in Emeryville, California, is a late-stage biotechnology company specializing in the design, development, and commercialization of gene therapies using proprietary adeno-associated virus (AAV) vectors. The company focuses on creating durable and disease-targeted genetic medicines for serious unmet medical conditions, with clinical programs primarily in ophthalmology and pulmonology. Its core products and pipeline include 4D-150, a Phase III candidate designed for multi-year sustained delivery of anti-VEGF agents to treat wet age-related macular degeneration and diabetic macular edema; 4D-710, an investigational therapy for cystic fibrosis lung disease using its A101 vector platform; and other programs such as 4D-175, 4D-725, and 4D-310 targeting geographic atrophy, alpha-1 antitrypsin deficiency, and other diseases. The company's proprietary technology platform, Therapeutic Vector Evolution, enables the invention of customized AAV vectors optimized for specific tissues and clinical administration routes while minimizing immune response, aiming to treat both rare genetic disorders and larger market diseases. 4D Molecular Therapeutics operates primarily in the United States but also engages in global collaborations and partnerships. It targets patients with genetic diseases that currently lack effective treatment options. Recent major developments include a strategic collaboration and licensing agreement with Pfizer focused on cardiac gene therapy vector discovery, which involves Pfizer's equity investment and milestone payments. In 2025, the company secured approximately $100 million through a common stock offering to support its clinical programs and pipeline advancement. Additionally, 4D Molecular Therapeutics gained alignment with the FDA to lift a clinical hold on its Phase 1/2 trial for 4D-310, and it obtained up to $11 million more funding from the Cystic Fibrosis Foundation to accelerate development of 4D-710. These initiatives represent significant operational progress and financial strengthening for advancing its gene therapy portfolio toward commercialization.
Company News
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Has Average Price Target of $28.90
4DMT to Host Investor Day on October 21, 2026
4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $28.56 Average PT from Brokerages
4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
4DMT Announces New Employment Inducement Grants
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics, Inc. $FDMT Stake Boosted by Bank of America Corp DE
Deutsche Bank AG Invests $9.46 Million in 4D Molecular Therapeutics, Inc. $FDMT
4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month High – Time to Buy?
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
10 Stock Picks to Celebrate 45 Years of Schaeffer's
4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population